Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS1/21 - Basic Clinical Chemistry - Serum

Deadline: 29.01.2021

RoM = robust average
SD = standard deviation
CV = coefficient of variation
Ntot = total number of the participants
Nout = number of results excluded before calculation

AV = assigned value
CRV = certified reference value
RV = reference value
CVE = consensus value from experts
CVP = consensus value from all participants
CVPG = consensus value from participants groups
U_{AV} = expanded uncertainty of the assigned value (k = 2)

Dmax = acceptable percent difference
LL = lower limit
UL = upper limit
Neva = number of evaluated participants
Nsuc = number of successful participants
Srel = success (relative)

Test	[unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel}	Traceability AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel}
(1) Sodium	[mmol/L]				207							0								207	204	99%
Samples and groups																						
Sample A		156	2,8	1,8	207							0			CRV 155,8	2,4	5%	148	164	207	205	99%
(2) Indirect ISE		156	2,7	1,8	188	0														188		
(3) Direct ISE		156	3,2	2,1	16	0														16		
Other					3	0														3		
															1x 1, 2x 99							
Sample B		133	2,1	1,6	207							0			CRV 132,5	2,0	5%	125	140	207	205	99%
(2) Indirect ISE		133	2,0	1,5	188	0														188		
(3) Direct ISE		134	3,5	2,6	16	0														16		
Other					3	0														3		
															1x 1, 2x 99							
(2) Potassium	[mmol/L]				207							0								207	195	94%
Samples and groups																						
Sample A		2,84	0,06	2,4	207							0			CRV 2,753	0,044	7%	2,56	2,95	207	195	94%
(2) Indirect ISE		2,84	0,06	2,3	189	0														189		
(3) Direct ISE		2,84	0,08	2,9	16	0														16		
Other					2	0														2		
															2x 99							
Sample B		5,80	0,11	2,0	207							0			CRV 5,764	0,086	7%	5,36	6,17	207	206	100%
(2) Indirect ISE		5,79	0,11	1,9	189	0														189		
(3) Direct ISE		5,85	0,13	2,3	16	0														16		
Other					2	0														2		
															2x 99							
(3) Chloride	[mmol/L]				207							207	199	96%						0		
Samples and groups																						
Sample A		140	2,7	1,9	207		CVP 140	0,46	7%	130	150	207	201	97%						0		
(3) Indirect ISE		140	2,6	1,9	187	0						187										
(4) Direct ISE		139	3,7	2,7	16	0						16										
Other					4	0						4										
							3x 2, 1x 99															
Sample B		114	2,7	2,4	207		CVP 114	0,47	7%	106	122	207	203	98%						0		
(3) Indirect ISE		114	2,7	2,4	187	0						187										
(4) Direct ISE		115	2,8	2,4	16	0						16										
Other					4	0						4										
							3x 2, 1x 99															
(4) Calcium	[mmol/L]				194							0								194	188	97%
Samples and groups																						
Sample A		1,98	0,05	2,8	194							0			CRV 1,941	0,029	8%	1,78	2,1	194	189	97%
(2) Phot. with o-cresolftalexon		1,97	0,06	3,2	22	0														22		
(3) Photom. with arsenazo III		1,99	0,06	3,5	105	0														105		

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS1/21 - Basic Clinical Chemistry - Serum

Deadline: 29.01.2021

Test / [unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability: AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel}	Traceability: AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel}
(4) Calcium [mmol/L]				194							0								194	188	97%
Samples and groups																					
Sample A	1,98	0,05	2,8	194							0			CRV	1,941	0,029	8%	1,78	2,1	194	189	97%
(4) Photomet. with NM-BAPTA	1,97	0,03	1,9	63	0														63		
Other				4	0														4		
Sample B	2,78	0,06	2,4	194							0			CRV	2,737	0,042	8%	2,51	2,96	194	193	99%
(2) Phot. with o-cresolftalexon	2,78	0,08	3,0	22	0														22		
(3) Photom. with arsenazo III	2,79	0,07	2,7	105	0														105		
(4) Photomet. with NM-BAPTA	2,78	0,05	1,8	63	0														63		
Other				4	0														4		
(5) Inorganic phosphate [mmol/L]				188							188	183	97%						0		
Samples and groups																					
Sample A	0,933	0,03	3,5	188		CVP 0,933	,0059	10%	0,839	1,03	188	185	98%						0		
(1) UV-molybdate method	0,932	0,03	3,5	182	0						182										
Other				6	0						6										
Sample B	1,34	0,03	2,9	188		CVP 1,34	,0069	10%	1,2	1,48	188	185	98%						0		
(1) UV-molybdate method	1,34	0,03	2,8	182	0						182										
Other				6	0						6										
(6) Iron [µmol/L]				176							176	173	98%						0		
Samples and groups																					
Sample A	32,6	0,96	2,9	176		CVP 32,6	0,18	15%	27,7	37,5	176	173	98%						0		
(2) Method with ferrozine/ferene	32,7	0,98	3,0	135	0						135										
(4) Method with TPTZ	32,3	0,78	2,4	41	0						41										
Sample B	42,5	1,0	2,5	176		CVP 42,5	0,19	15%	36,1	48,9	176	175	99%						0		
(2) Method with ferrozine/ferene	42,5	1,1	2,5	135	0						135										
(4) Method with TPTZ	42,4	0,98	2,3	41	0						41										
(7) Magnesium [mmol/L]				184							0								184	180	98%
Samples and groups																					
Sample A	0,977	0,02	3,0	184							0			CRV	0,959	0,015	15%	0,815	1,11	184	183	99%
(2) Photometry	0,979	0,02	2,9	156	0														156		
(4) UV enzyme method	0,970	0,03	3,6	28	0														28		
Sample B	1,60	0,04	2,8	184							0			CRV	1,574	0,025	15%	1,33	1,82	184	181	98%
(2) Photometry	1,60	0,04	2,7	156	0														156		
(4) UV enzyme method	1,62	0,05	3,6	28	0														28		
(8) Lithium [mmol/L]				25							0								25	24	96%
Samples and groups																					
Sample A	1,29	0,05	4,4	25							0			CRV	1,309	0,020	12%	1,15	1,47	25	25	100%
(1) Flame emission phot.	1,29	0,04	3,4	5	0														5		
(3) ISE	1,30	0,03	2,3	7	0														7		
(4) Photometry	1,28	0,06	4,9	12	0														12		
Other				1	0														1		
Sample B	1,21	0,05	4,5	25							0			CRV	1,244	0,019	12%	1,09	1,4	25	24	96%

4x 6

4x 6

1x 0, 4x 2, 1x 3

1x 0, 4x 2, 1x 3

1x 2

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS1/21 - Basic Clinical Chemistry - Serum

Deadline: 29.01.2021

Test	[unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability								Traceability							
								AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel}		AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel}
(8) Lithium	[mmol/L]				25								0									25	24	96%
Samples and groups																								
Sample B		1,21	0,05	4,5	25								0			CRV	1,244	0,019	12%	1,09	1,4	25	24	96%
(1) Flame emission phot.		1,19	0,05	4,4	5	0																5		
(3) ISE		1,23	0,03	2,4	7	0																7		
(4) Photometry		1,21	0,06	4,9	12	1																12		
Other					1	0																1		
																1x 2								
(9) Total protein	[g/L]				198								0									198	196	99%
Samples and groups																								
Sample A		59,6	1,6	2,6	198								0			CRV	59,44	0,70	9%	54	64,8	198	196	99%
(1) Biuret		59,6	1,6	2,6	198	0																198		
Sample B		85,3	2,2	2,6	198								0			CRV	86,11	1,0	9%	78,3	93,9	198	198	100%
(1) Biuret		85,3	2,2	2,6	198	0																198		
(10) Albumin	[g/L]				196								196	193	98%							0		
Samples and groups																								
Sample A		39,0	1,4	3,5	196		CVP	39	0,24	10%	35,1	42,9	196	193	98%							0		
(1) BCG		39,1	1,3	3,4	179	0							179											
(2) BCP		38,5	1,3	3,3	16	0							16											
Other					1	0							1											
							1x 0																	
Sample B		54,4	1,6	3,0	196		CVP	54,4	0,28	10%	48,9	59,9	196	194	99%							0		
(1) BCG		54,4	1,6	3,0	179	0							179											
(2) BCP		54,7	1,8	3,2	16	0							16											
Other					1	1							1											
							1x 0																	
(11) Osmolality	[mmol/kg]				78								78	71	91%							0		
Samples and groups																								
Sample A		337	5,7	1,7	78		CVP	337	1,6	5%	320	354	78	73	94%							0		
(1) Osmometer		337	5,7	1,7	78	0							78											
Sample B		299	7,5	2,5	78		CVP	299	2,1	5%	284	314	78	74	95%							0		
(1) Osmometer		299	7,5	2,5	78	0							78											
(12) Lactate	[mmol/L]				93								93	93	100%							0		
Samples and groups																								
Sample A		3,94	0,15	3,9	93		CVP	3,94	0,039	15%	3,34	4,54	93	93	100%							0		
(1) UV enzyme method		3,96	0,17	4,2	35	0							35											
(2) Enzyme electrodes		4,04	0,40	9,9	8	0							8											
(3) Photometric enzyme method		3,92	0,14	3,5	50	0							50											
Sample B		2,96	0,11	3,7	93		CVP	2,96	0,028	15%	2,51	3,41	93	93	100%							0		
(1) UV enzyme method		2,96	0,11	3,8	35	0							35											
(2) Enzyme electrodes		3,04	0,42	14	8	0							8											
(3) Photometric enzyme method		2,94	0,09	3,1	50	0							50											
(13) Bilirubin total	[µmol/L]				209								0									209	203	97%
Samples and groups																								
Sample A		32,4	2,8	8,5	209								0			CRV	30,8	1,0	21%	24,3	37,3	209	204	98%

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS1/21 - Basic Clinical Chemistry - Serum

Deadline: 29.01.2021

Test [unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel}	Traceability AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel}
(13) Bilirubin total [µmol/L]				209							0								209	203	97%
Samples and groups																					
Sample A	32,4	2,8	8,5	209							0			CRV	30,8	1,0	21%	24,3	37,3	209	204	98%
(1) Jendrassik-Gróf	32,9	2,4	7,3	27	0														27		
(2) DCA, DPD	32,0	2,7	8,5	162	0														162		
(4) Oxidation-reduction methods	34,5	1,8	5,1	20	0														20		
Sample B	32,9	2,8	8,5	209							0			CRV	32	0,80	21%	25,2	38,8	209	205	98%
(1) Jendrassik-Gróf	33,4	3,0	8,9	27	0														27		
(2) DCA, DPD	32,6	2,8	8,4	162	0														162		
(4) Oxidation-reduction methods	34,9	1,9	5,5	20	0														20		
(15) Cholesterol [mmol/L]				197							7	7	100%						190	186	98%
Samples and groups																					
Sample A	3,37	0,13	4,0	197							7	7	100%						190	187	98%
(1) Enzyme method CHOD-PAP	3,38	0,13	3,8	189	0									CRV	3,447	0,034	9%	3,13	3,76	189		
(1) Enzyme method CHOD-PAP; (149) Siemens (Dade, BN, Dimension)	2,84	0,19	6,5	7	0	CVPG	2,84	0,18	7,5%	2,62	3,06	7										
Other				1	0									1x 99					1		
Sample B	5,07	0,22	4,4	197							7	7	100%						190	188	99%
(1) Enzyme method CHOD-PAP	5,08	0,21	4,2	189	0									CRV	5,129	0,051	9%	4,66	5,6	189		
(1) Enzyme method CHOD-PAP; (149) Siemens (Dade, BN, Dimension)	4,66	0,22	4,6	7	0	CVPG	4,66	0,21	7,5%	4,31	5,01	7										
Other				1	0									1x 99					1		
(16) Glucose [mmol/L]				211							0								211	209	99%
Samples and groups																					
Sample A	6,58	0,18	2,7	211							0			CRV	6,53	0,065	8%	6	7,06	211	211	100%
(1) GOD photometry	6,64	0,15	2,2	39	0														39		
(2) GOD electrochemical	6,61	0,05	0,79	5	0														5		
(3) Method with hexokinase	6,57	0,19	2,9	167	0														167		
Sample B	5,37	0,16	3,0	211							0			CRV	5,467	0,055	8%	5,02	5,91	211	209	99%
(1) GOD photometry	5,47	0,16	2,8	39	0														39		
(2) GOD electrochemical	5,39	0,02	0,41	5	0														5		
(3) Method with hexokinase	5,35	0,16	2,9	167	0														167		
(17) Uric acid [µmol/L]				205							0								205	205	100%
Samples and groups																					
Sample A	418	14	3,4	205							0			CRV	415,2	4,2	12%	365	466	205	205	100%
(2) Enzyme-photomet. m.	418	14	3,4	205	0														205		
Sample B	612	17	2,8	205							0			CRV	612	6,1	12%	538	686	205	205	100%
(2) Enzyme-photomet. m.	612	17	2,8	205	0														205		
(18) Urea [mmol/L]				209							0								209	208	100%
Samples and groups																					
Sample A	19,0	0,71	3,8	209							0			CRV	19,4	0,19	15%	16,4	22,4	209	209	100%
(1) UV enzymatic m.(GMD)	19,0	0,72	3,8	204	0														204		
Other				5	0									4x 5, 1x 99					5		
Sample B	15,0	0,52	3,5	209							0			CRV	15,3	0,15	15%	13	17,6	209	208	100%

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS1/21 - Basic Clinical Chemistry - Serum

Deadline: 29.01.2021

Test [unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability: AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel}	Traceability: AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel}
(18) Urea [mmol/L]				209							0								209	208	100%
Samples and groups																					
Sample B	15,0	0,52	3,5	209							0			CRV	15,3	0,15	15%	13	17,6	209	208	100%
(1) UV enzymatic m.(GMD)	14,9	0,53	3,5	204	0															204		
Other				5	0															5		
														4x 5, 1x 99								
(19) Creatinine [µmol/L]				212							0								212	198	93%
Samples and groups																					
Sample A	165	5,8	3,5	212							0			CRV	164,8	1,6	13%	143	187	212	212	100%
(1) Jaffe	166	6,4	3,8	95	0															95		
(3) Enzyme	165	5,2	3,2	117	0															117		
Sample B	150	9,0	6,0	212							0			CRV	146,6	1,7	13%	127	166	212	198	93%
(1) Jaffe	156	10	6,4	95	0															95		
(3) Enzyme	146	5,4	3,7	117	0															117		
(20) Triacylglycerols [mmol/L]				195							0								195	193	99%
Samples and groups																					
Sample A	1,41	0,05	3,7	195							0			CRV	1,369	0,016	15%	1,16	1,58	195	195	100%
(1) Photometric enzyme (GPO-PAP)	1,41	0,05	3,7	192	0															192		
Other				3	0															3		
														3x 2								
Sample B	1,33	0,04	3,7	195							0			CRV	1,318	0,013	15%	1,12	1,52	195	193	99%
(1) Photometric enzyme (GPO-PAP)	1,33	0,04	3,7	192	0															192		
Other				3	0															3		
														3x 2								
(21) ALP [µkat/L]				203							0								203	203	100%
Samples and groups																					
Sample A	4,36	0,39	9,0	203							0			CRV	4,568	0,10	28%	3,28	5,85	203	203	100%
(3) IFCC method	4,36	0,40	9,1	202	0															202		
Other				1	0															1		
														1x 1								
Sample B	2,62	0,19	7,1	203							0			CRV	2,731	,0080	28%	1,96	3,5	203	203	100%
(3) IFCC method	2,61	0,19	7,1	202	0															202		
Other				1	0															1		
														1x 1								
(22) alpha-amylase [µkat/L]				200							6	6	100%						194	189	97%
Samples and groups																					
Sample A	8,15	0,51	6,2	200							6	6	100%						194	189	97%
(1) IFCC method	8,12	0,48	5,9	194	0									CRV	8,213	0,22	15%	6,98	9,45	194		
(1) IFCC method; (149) Siemens (Dade, BN, Dimension)	10,1	0,23	2,3	6	0	CVPG	10,1	0,32	9%	9,19	11,1	6										
Sample B	8,28	0,50	6,0	200							6	6	100%						194	190	98%
(1) IFCC method	8,25	0,48	5,8	194	0									CRV	8,325	0,023	15%	7,07	9,58	194		
(1) IFCC method; (149) Siemens (Dade, BN, Dimension)	9,92	0,16	1,6	6	0	CVPG	9,92	0,22	9%	9,02	10,9	6										

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS1/21 - Basic Clinical Chemistry - Serum

Deadline: 29.01.2021

Test / [unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability: AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel}	Traceability:	AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel}
(23) AST [µkat/L]				209							0									209	195	93%
Samples and groups																						
Sample A	5,59	0,24	4,3	209							0			CRV	5,711	0,13	15%	4,85	6,57	209	201	96%
(1) IFCC method	5,60	0,24	4,2	208	0															208		
Other				1	0															1		
														1x 99								
Sample B	3,27	0,16	4,7	209							0			CRV	3,287	0,013	15%	2,79	3,79	209	198	95%
(1) IFCC method	3,27	0,15	4,7	208	0															208		
Other				1	0															1		
														1x 99								
(24) ALT [µkat/L]				210							0									210	206	98%
Samples and groups																						
Sample A	3,02	0,13	4,4	210							0			CRV	3,084	0,078	15%	2,62	3,55	210	210	100%
(1) IFCC method	3,02	0,13	4,4	209	0															209		
Other				1	0															1		
														1x 99								
Sample B	1,22	0,08	7,0	210							0			CRV	1,222	0,013	15%	1,03	1,41	210	206	98%
(1) IFCC method	1,22	0,08	7,0	209	0															209		
Other				1	0															1		
														1x 99								
(26) CK [µkat/L]				193							0									193	193	100%
Samples and groups																						
Sample A	5,45	0,37	6,7	193							0			CRV	5,598	0,17	20%	4,47	6,72	193	193	100%
(1) IFCC method	5,45	0,37	6,7	193	0															193		
Sample B	3,44	0,22	6,3	193							0			CRV	3,469	0,037	20%	2,77	4,17	193	193	100%
(1) IFCC method	3,44	0,22	6,3	193	0															193		
(27) gamma-GT [µkat/L]				205							0									205	198	97%
Samples and groups																						
Sample A	2,47	0,11	4,4	205							0			CRV	2,561	0,065	15%	2,17	2,95	205	199	97%
(1) IFCC method	2,47	0,11	4,4	205	0															205		
Sample B	2,09	0,08	4,2	205							0			CRV	2,175	,0080	15%	1,84	2,51	205	199	97%
(1) IFCC method	2,09	0,08	4,2	205	0															205		
(28) LD [µkat/L]				158							0									158	158	100%
Samples and groups																						
Sample A	2,78	0,11	3,9	158							0			CRV	2,902	0,067	18%	2,37	3,43	158	158	100%
(3) IFCC method	2,78	0,11	3,9	158	0															158		
Sample B	7,35	0,20	2,7	158							0			CRV	7,378	0,033	18%	6,05	8,71	158	158	100%
(3) IFCC method	7,35	0,20	2,7	158	0															158		
(29) Lipase [µkat/L]				118							108	104	96%							0		
Samples and groups																						
Sample A	0,972	0,11	11	118							108	105	97%							0		
(0) Not specified; (1) Abbott	1,05	0,03	3,3	11	0	CVPG	1,05	0,026	24%	0,798	1,31	11										
(0) Not specified; (46) Erba Lachema	0,891	0,04	5,2	5	0	CVPG	0,891	0,13	24%	0,677	1,11	5										
(0) Not specified; (58) Beckman Coulter (AU)	1,04	0,06	5,7	28	0	CVPG	1,04	0,028	24%	0,79	1,29	28										
(0) Not specified; (60) Roche	0,895	0,03	3,4	44	0	CVPG	0,895	0,011	24%	0,68	1,11	44										

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS1/21 - Basic Clinical Chemistry - Serum

Deadline: 29.01.2021

Test [unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel}	Traceability AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel}
(29) Lipase [µkat/L]				118							108	104	96%						0		
Samples and groups																					
Sample A	0,972	0,11	11	118							108	105	97%						0		
(0) Not specified; (149) Siemens (Dade, BN, Dimension)	3,55	0,01	0,42	5	0	CVPG 3,55	0,042	24%	2,69	4,41	5										
(0) Not specified; (162) Siemens (Atellica)	1,05	0,07	7,1	8	0	CVPG 1,05	0,056	24%	0,798	1,31	8										
(0) Not specified; (179) Siemens	1,07	0,03	3,5	7	0	CVPG 1,07	0,036	24%	0,813	1,33	7										
Other				10	0						0										
					3x 0/12, 2x 0/49, 1x 0/116, 1x 0/177, 3x 0/178																
Sample B	1,80	0,18	9,9	118							108	105	97%						0		
(0) Not specified; (1) Abbott	1,78	0,08	4,6	11	0	CVPG 1,78	0,060	24%	1,35	2,21	11										
(0) Not specified; (46) Erba Lachema	1,52	0,18	12	5	0	CVPG 1,52	0,50	24%	1,15	1,89	5										
(0) Not specified; (58) Beckman Coulter (AU)	1,86	0,07	4,2	28	0	CVPG 1,86	0,037	24%	1,41	2,31	28										
(0) Not specified; (60) Roche	1,72	0,07	4,2	44	0	CVPG 1,72	0,027	24%	1,3	2,14	44										
(0) Not specified; (149) Siemens (Dade, BN, Dimension)	6,86	0,42	6,1	5	0	CVPG 6,86	1,2	24%	5,21	8,51	5										
(0) Not specified; (162) Siemens (Atellica)	2,03	0,08	4,4	8	0	CVPG 2,03	0,068	24%	1,54	2,52	8										
(0) Not specified; (179) Siemens	2,06	0,08	4,3	7	0	CVPG 2,06	0,086	24%	1,56	2,56	7										
Other				10	0						0										
					3x 0/12, 2x 0/49, 1x 0/116, 1x 0/177, 3x 0/178																
(30) Cholinesterase [µkat/L]				73							70	67	96%						0		
Samples and groups																					
Sample A	121	5,3	4,4	73							70	67	96%						0		
(1) Standard method	121	4,8	4,0	70	0	CVP 121	1,4	12%	106	136	70										
Other				3	0						0										
					3x 1/162																
Sample B	171	7,9	4,6	73							70	67	96%						0		
(1) Standard method	170	7,2	4,2	70	0	CVP 170	2,1	12%	149	191	70										
Other				3	0						0										
					3x 1/162																
(31) Albumin (elpho) [-]				60							60	57	95%						0		
Samples and groups																					
Sample A	0,645	0,03	5,9	60		CVP 0,645	0,012	15%	0,548	0,742	60	60	100%						0		
(0) Not specified	0,645	0,03	5,9	60	0						60										
Sample B	0,634	0,05	8,2	60		CVP 0,634	0,016	15%	0,538	0,73	60	57	95%						0		
(0) Not specified	0,634	0,05	8,2	60	0						60										
(32) gamma-globuline (elpho) [-]				60							60	55	92%						0		
Samples and groups																					
Sample A	0,123	0,01	12	60		CVP 0,123	,0045	30%	0,086	0,16	60	58	97%						0		
(0) Not specified	0,123	0,01	12	60	0						60										
Sample B	0,124	0,01	13	60		CVP 0,124	,0049	30%	0,086	0,162	60	56	93%						0		
(0) Not specified	0,124	0,01	13	60	0						60										
(35) alpha-amylase pancreatic [µkat/L]				78							78	78	100%						0		
Samples and groups																					
Sample A	7,24	0,29	4,0	78		CVP 7,24	0,080	18%	5,93	8,55	78	78	100%						0		

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS1/21 - Basic Clinical Chemistry - Serum

Deadline: 29.01.2021

Test	[unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability								Traceability							
								AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel}	AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel}
(35) alpha-amylase pancreatic	[µkat/L]				78								78	78	100%						0		
Samples and groups																							
Sample A		7,24	0,29	4,0	78		CVP	7,24	0,080	18%	5,93	8,55	78	78	100%						0		
(1) With IFCC calibration		7,24	0,29	4,0	78	0							78										
Sample B		7,21	0,28	3,9	78		CVP	7,21	0,078	18%	5,91	8,51	78	78	100%						0		
(1) With IFCC calibration		7,21	0,28	3,9	78	0							78										
(36) Calcium ionised	[mmol/L]				38								38	36	95%						0		
Samples and groups																							
Sample A		1,32	0,04	3,7	38		CVP	1,32	0,019	10%	1,18	1,46	38	36	95%						0		
(2) Direct ISE		1,32	0,04	3,6	35	0							35										
Other					3	0	3x 1						3										
Sample B		1,68	0,04	2,4	38		CVP	1,68	0,016	10%	1,51	1,85	38	37	97%						0		
(2) Direct ISE		1,68	0,03	2,2	35	0							35										
Other					3	0	3x 1						3										

st_kn_np

End of report

Printed: 04.02.2021